德琪医药-B（06996）于2026年3月5日披露截至2026年2月28日止的股份变动月报表。本期内公司股本未发生任何增发、回购或注销，整体规模保持稳定。
截至2026年2月底，公司法定股本为2,000,000,000股，面值每股0.0001美元，合计200,000美元，与上月持平；已发行普通股数量维持在679,244,132股，另有202,500股库存股份，总股本合计679,446,632股，报告期内无变动。
根据月报披露，2020股权激励计划中有100,000份期权在本期失效，期末剩余25,612,720份期权。若将现有期权与2022年受限制股份单位计划的归属权益全部行使，合计最多可新增发行或转让56,026,007股。
公司同时确认已符合香港联交所对于上市公司公众持股比例的相关要求。本次公告由主席梅建明博士签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.